The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: Use at a concentration of 5 µg/ml.
This antibody gave a positive result in ELISA against the immunizing peptide. Antibody detection limit dilution 1:32,000.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Involved in EGFR signaling.
Isoform 1 and isoform 2 are co-expressed in placenta, liver, lung, kidney and pancreas. Only isoform 1 is detected in skeletal muscle, brain and heart.
Involvement in disease
Defects in CCDC50 are the cause of deafness autosomal dominant type 44 (DFNA44) [MIM:607453]. A form of non-syndromic hearing loss. It is initially moderate and affects mainly low to mid frequencies. Later, it progresses to involve all the frequencies and leads to a profound hearing loss by the 6th decade. The onset of the hearing loss occurs in the first decade of life.
Phosphorylated on tyrosine residues.
Cytoplasm. Associated with microtubules of the cytoskeleton and mitotic apparatus.
ab32884 at 5ug/ml staining CCDC50 in human pancreas tissue section by Immunohistochemistry (Formalin/PFA fixed paraffin-embedded sections). Tissue underwent antigen retrieval in steam with citrate buffer (pH 6.0). A AP-staining procedure was used for detection.